# Centrexion Therapeutics Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/centrexion-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.centrexion.com
- Total disclosed funding: $91M
- Latest round: Series D (Jan 2, 2018)
- Investors on record: 7

## About

Founded in 2013, chaired by Jeffery B. Kindler as CEO and based in Massachusetts, the US, Centrexion Therapeutics Corporation, is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel, non-opioid, and non-addictive therapies for chronic pain. In 2020, Centrexion Therapeutics Corporation raised USD 40.5 million from Lilly Asia Ventures, Exome Asset Management, and Solar Capital among others. As of 2021, the company employs over 20 employees. 

The company’s drug candidates include topical gel, joint or deeper tissue injection, spinal delivery, and oral therapies. Centrexion Therapeutics’ develops therapies that target the origin of the pain signal to relieve chronic pain. The firm makes use of big data analytics, translational science, and early-stage clinical trials to develop therapies for disease areas such as oncology. The company’s flagship product and the novel patented candidate, CNTX-4975, provides a non-opioid and non-addictive method to relieve chronic pain caused by osteoarthritis of the knee and includes neuropathic and inflammatory pain, which are associated with a wide variety of diseases. The company’s product candidate also includes  CNTX-0290 for neuropathic, musculoskeletal and inflammatory pain, CNTX-6970 for inflammatory and osteoarthritis pain, CNTX-2022 for superficial pain and CNTX-6016 for diabetic neuropathic pain. 

The company plans on utilizing the investments acquired in 2020 to strengthen its ability to advance the existing drug candidate pipeline that extends from mid-stage development to large registrational clinical trials. Additionally, the firm plans to leverage its expertise by pursuing licensing opportunities for promising mid-stage assets across many target therapeutics areas. Centrexion Therapeutics plans on advancing the development of CNTX- 4975 through Phase 3 registration trials and its commercialization on priority.

## Funding rounds

- Series D, Jan 2, 2018, $67M — InterWest Partners, New Enterprise Associates, ArrowMark Partners, 6 Dimensions Capital, Clough Capital Partners, Efung Capital, Quan Capital
- Series B, Dec 3, 2013, $15M — InterWest Partners
- Series A, Nov 23, 2013, $8.8M — InterWest Partners

## Investors

- InterWest Partners (https://capitalatlas.ai/funds/interwest-partners) — Series A, Series B, Series D
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series D
- ArrowMark Partners — Series D
- 6 Dimensions Capital (https://capitalatlas.ai/funds/6-dimensions-capital) — Series D
- Clough Capital Partners — Series D
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series D
- Quan Capital (https://capitalatlas.ai/funds/quan-capital) — Series D